Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2006 May 4;35(3):366–377. doi: 10.1165/rcmb.2005-0452OC

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2006, American Thoracic Society

PMC Copyright notice

Figure 2. — Treatment with pirfenidone in a dose-dependent manner prevents the development of AHR (A) and inflammatory cell accumulation in BALF (B). Penh values to increasing concentrations of inhaled MCh were measured as described in Materials and Methods in nonsensitized/challenged mice receiving saline, OVA-sensitized/OVA-challenged mice receiving saline, nonsensitized/challenged mice receiving pirfenidone, and OVA-sensitized/OVA-challenged mice receiving pirfenidone. Results for each group are expressed as the mean ± SD. n = 16 in each group. ^#Significant differences (P < 0.05) between nonsensitized/OVA-challenged mice (Non-sensitized/OVA/Control) and OVA-sensitized/OVA-challenged mice (OVA/OVA/Control). *Significant differences (P < 0.05) between OVA-sensitized/OVA-challenged control mice (receiving saline) (OVA/OVA/Control) and pirfenidone-treated mice (OVA/OVA/PFD).